Olga Usalka

Dr. Olga Usalka

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
RZRoman Germanovich Zenkov
Roman Germanovich Zenkov
OVOlga Aleksandrovna Vlasova
Olga Aleksandrovna Vlasova
VMVarvara Maksimova
Varvara Maksimova
TFTimur Igorevich Fetisov
Timur Igorevich Fetisov
NKNatalia Y. Karpechenko
Natalia Y. Karpechenko
KKKirill Kirsanov
Kirill Kirsanov
Novel indolocarbazole derivatives named LCS were synthesized by our research group. Two of them were selected as the most active anticancer agents in vivo. We studied the mechanisms of anticancer activity in accordance with the previously described effects of indolocarbazoles. Cytotoxicity was estimated by MTT assay. We analyzed LCS-DNA interactions by circular dichroism in cholesteric liquid crystals and fluorescent indicator displacement assay. The effect on the activity of topoisomerases I and II was studied by DNA relaxation assay. Expression of interferon signaling target genes was estimated by RT-PCR. Chromatin remodeling was analyzed–the effect on histone H1 localization and reactivation of epigenetically silenced genes. LCS-induced change in the expression of a wide gene set was counted by means of PCR array. Our study revealed the cytotoxic activity of the compounds against 11 cancer cell lines and it was higher than in immortalized cells. Both compounds bind DNA; binding constants were estimated—LCS-1208 demonstrated higher affinity than LCS-1269; it was shown that LCS-1208 intercalates into DNA that is typical for rebeccamycin derivatives. LCS-1208 also inhibits topoisomerases I and IIα. Being a strong intercalator and topoisomerase inhibitor, LCS-1208 upregulates the expression of interferon-induced genes. In view of LCSs binding to DNA we analyzed their influence on chromatin stability and revealed that LCS-1269 displaces histone H1. Our analysis of chromatin remodeling also included a wide set of epigenetic experiments in which LCS-1269 demonstrated complex epigenetic activity. Finally, we revealed that the antitumor effect of the compounds is based not only on binding to DNA and chromatin remodeling but also on alternative mechanisms. Both compounds induce expression changes in genes involved in neoplastic transformation and target genes of the signaling pathways in cancer cells. Despite of being structurally similar, each compound has unique biological activities. The effects of LCS-1208 are associated with intercalation. The mechanisms of LCS-1269 include influence on higher levels such as chromatin remodeling and epigenetic effects.

15 September 2019 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VMVarvara Maksimova
Varvara Maksimova
PBP. E. Bugaeva
P. E. Bugaeva
EZE. M. Zhidkova
E. M. Zhidkova
OUOlga Usalka
Olga Usalka
ELEkaterina Lesovaya
Ekaterina Lesovaya
KKKirill Kirsanov
Kirill Kirsanov
Objective. Review of the modern methodological approaches for testing and studying the epigenetic activity of xenobiotics.Materials and methods. In preparing the review, we used information databases of biomedical literature SciVerse Scopus (538), PubMed (746), Web of Science (625), RSCI (45). To obtain full-text documents, electronic resources of PubMed Central (PMC), Research Gate, RSCI, CyberLeninka were used. In the text of the review, 87 modern publications (2010–2019) were cited, as well as 17 earlier articles published by the founders of the methods, which are used today.Results. In the review, current data on epigenetic regulation for gene expression at the level of DNA methylation and histone modification are discussed, in vitro model systems and model organisms are described, and modern methods for screening of epigenetically active xenobiotics are presented.Conclusion. Modern data concerning the mechanisms of epigenetic regulation of gene expression, the usage of existing model systems and model organisms, as well as the application of various methodological approaches and techniques, allow extensive screening of xenobiotics (including drugs and compounds synthesized for national economic tasks) for epigenetic activity. The identification of epigenetically active compounds is important in terms of improving the prevention and treatment of a number of diseases and, in particular, malignant neoplasms.

Verified
Journal Article
Open access
PDF file
VMVarvara Maksimova
Varvara Maksimova
VPValeriia Popova
Valeriia Popova
APAnzhelika Prus
Anzhelika Prus
ELEvgeniya Lylova
Evgeniya Lylova
OUOlga Usalka
Olga Usalka
KKKirill Kirsanov
Kirill Kirsanov
The development of malignant tumors is caused by a complex combination of genetic mutations and epigenetic alterations, the latter of which are induced by either external environmental factors or signaling disruption following genetic mutations. Some types of cancer demonstrate a significant increase in epigenetic enzymes, and targeting these epigenetic alterations represents a compelling strategy to reverse cell transcriptome to the normal state, improving chemotherapy response. Curaxin CBL0137 is a new potent anticancer drug that has been shown to activate epigenetically silenced genes. However, its detailed effects on the enzymes of the epigenetic system of transcription regulation have not been studied. Here, we report that CBL0137 inhibits the expression of DNA methyltransferase DNMT3a in HeLa TI cells, both at the level of mRNA and protein, and it decreases the level of integral DNA methylation in Ca Ski cells. For the first time, it is shown that CBL0137 decreases the level of BET family proteins, BRD2, BRD3, and BRD4, the key participants in transcription elongation, followed by the corresponding gene expression enhancement. Furthermore, we demonstrate that CBL0137 does not affect the mechanisms of histone acetylation and methylation. The ability of CBL0137 to suppress DNMT3A and BET family proteins should be taken into consideration when combined chemotherapy is applied. Our data demonstrate the potential of CBL0137 to be used in the therapy of tumors with corresponding aberrant epigenetic profiles.

23 February 2026 in Epigenomes
Verified
Journal Article
Open access
PDF file
VMVarvara Maksimova
Varvara Maksimova
VPValeriia Popova
Valeriia Popova
AKAlyona Kholodova
Alyona Kholodova
YMYulia Makus
Yulia Makus
OUOlga Usalka
Olga Usalka
KKKirill Kirsanov
Kirill Kirsanov
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.

2 September 2020 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
VMVarvara Maksimova
Varvara Maksimova
YMYulia Makus
Yulia Makus
OUOlga Usalka
Olga Usalka
ELEvgeniya Lylova
Evgeniya Lylova
PBP. E. Bugaeva
P. E. Bugaeva
KKKirill Kirsanov
Kirill Kirsanov
ЭПИГЕНЕТИЧЕСКИЕ ЭФФЕКТЫ ЭНЗАСТАУРИНА – НОВЫЙ АСПЕКТ В МЕХАНИЗМЕ ДЕЙСТВИЯ ПРОТИВООПУХОЛЕВОГО ПРЕПАРАТА ИЗ ГРУППЫ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ

9 September 2024 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
VMVarvara Maksimova
Varvara Maksimova
YMYulia Makus
Yulia Makus
VPValeriia Popova
Valeriia Popova
OUOlga Usalka
Olga Usalka
GBGennady A. Belitsky
Gennady A. Belitsky
KKKirill Kirsanov
Kirill Kirsanov
Background. DNA methylation is a crucial mechanism of epigenetic regulation of transcription. Disturbances in DNA methylation mechanism are associated with various malignancies such as acute myeloid leukaemia, breast cancer, prostate cancer, etc. Influencing the functional status of DNA methyltransferases (DNMTs) enzymes and TET family proteins (TETs), which regulate DNA methylation and demethylation, is the basis of epigenetic anticancer therapy approach. In this review, we have considered the challenges and prospects of nucleoside and non-nucleoside inhibitors of DNMTs as well as TETs inhibitors. The results of clinical trials on the efficacy of DNMTs inhibitors used individually and as part of combination chemotherapy conducted over the last 15 years are also evaluated. Material and Methods. Sources were searched in PubMed, ScienceDirect, Web of Science, eLibrary, CyberLeninka. More than 700 publications were used in the analysis, but the review included mainly works of the last 10 years. A number of articles published earlier than 2015 were used for historical reference. Results. The review provides information on current advances in the development and study of epigenetically active compounds whose action is aimed at the regulation of DNA methylation. Data on the in vitro and in vivo effects of agents considered for use in the therapy of various malignancies are presented. In addition, the data of clinical trials of the most promising epigenetic modulators are presented.